{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:54:43Z","timestamp":1790060083908,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jhltonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Heart and Lung Transplantation"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.healun.2015.04.001","type":"journal-article","created":{"date-parts":[[2015,5,3]],"date-time":"2015-05-03T03:08:24Z","timestamp":1430622504000},"page":"1283-1291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab"],"prefix":"10.1016","volume":"34","author":[{"given":"David","family":"Ansari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars H.","family":"Lund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josef","family":"Stehlik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodil","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"H\u00f6glund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leah","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.healun.2015.04.001_bib1","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.athoracsur.2003.07.006","article-title":"Drug immunosuppression therapy for adult heart transplantation. Part 1: immune response to allograft and mechanism of action of immunosuppressants","volume":"77","author":"Mueller","year":"2004","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.healun.2015.04.001_bib2","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.healun.2010.05.034","article-title":"The International Society of Heart and Lung Transplantation guidelines for the care of heart transplant recipients","volume":"29","author":"Costanzo","year":"2010","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib3","series-title":"Principles and practice","article-title":"Immunotherapy in transplantation","author":"Kaplan","year":"2012"},{"key":"10.1016\/j.healun.2015.04.001_bib4","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.healun.2006.09.002","article-title":"Basiliximab versus rabbit anti-thymocyte globulin for induction therapy in patients after heart transplantation","volume":"25","author":"Flaman","year":"2006","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib5","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.healun.2007.05.002","article-title":"Lower risk of infectious deaths in cardiac transplant patients receiving basiliximab versus anti-thymocyte globulin as induction therapy","volume":"26","author":"Mattei","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib6","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1016\/j.healun.2012.08.002","article-title":"The Registry of the International Society for Heart and Lung Transplantation: 29th official adult heart transplant report\u20142012","volume":"31","author":"Stehlik","year":"2012","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib7","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1177\/152692480901900408","article-title":"Induction immunosuppression for orthotopic heart transplantation: a review","volume":"19","author":"Ensor","year":"2009","journal-title":"Prog Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib8","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1111\/tri.12107","article-title":"Induction therapy in heart transplantation: where are we now?","volume":"26","author":"Aliabadi","year":"2013","journal-title":"Transpl Int"},{"key":"10.1016\/j.healun.2015.04.001_bib9","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.healun.2011.01.716","article-title":"Steering Group, UK Cardiothoracic Transplant Audit. Antithymocyte globulin induction therapy for adult heart transplantation: a UK national study","volume":"30","author":"Emin","year":"2011","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib10","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.critrevonc.2004.11.010","article-title":"Cancer incidence after immunosuppressive treatment following kidney transplantation","volume":"56","author":"Andres","year":"2005","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.healun.2015.04.001_bib11","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1016\/j.healun.2004.09.010","article-title":"A multicenter, prospective, randomized, double-blind trial of basiliximab in heart transplantation","volume":"24","author":"Mehra","year":"2005","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib12","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.healun.2007.01.006","article-title":"Basiliximab and rabbit anti-thymocyte globulin for prophylaxis of acute rejection after heart transplantation: a non-inferiority trial","volume":"26","author":"Carrier","year":"2007","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib13","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.transproceed.2008.07.113","article-title":"Induction immunosuppression with basiliximab in heart transplantation","volume":"40","author":"Chou","year":"2008","journal-title":"Transplant Proc"},{"key":"10.1016\/j.healun.2015.04.001_bib14","series-title":"Model-building strategies and methods for logistic regression, in applied logistic regression","author":"Hosmer","year":"2013"},{"key":"10.1016\/j.healun.2015.04.001_bib15","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/sim.4067","article-title":"Multiple imputation using chained equations: issues and guidance for practice","volume":"30","author":"White","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.healun.2015.04.001_bib16","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1097\/00007890-199901270-00016","article-title":"Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody. United States Simulect Renal Study Group","volume":"67","author":"Kahan","year":"1999","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2015.04.001_bib17","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S0140-6736(97)09278-7","article-title":"Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group","volume":"350","author":"Nashan","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.healun.2015.04.001_bib18","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/01.TP.0000109643.32659.C4","article-title":"Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials","volume":"77","author":"Webster","year":"2004","journal-title":"Transplantation"},{"key":"10.1016\/j.healun.2015.04.001_bib19","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1056\/NEJMoa060068","article-title":"Rabbit antithymocyte globulin versus basiliximab in renal transplantation","volume":"355","author":"Brennan","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.04.001_bib20","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0966-3274(01)00048-X","article-title":"US Thymoglobulin Multi-Center Study Group. Total and active Thymoglobulin levels: effects of dose and sensitization on serum concentrations","volume":"9","author":"Regan","year":"2001","journal-title":"Transpl Immunol"},{"key":"10.1016\/j.healun.2015.04.001_bib21","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1016\/j.healun.2014.08.003","article-title":"Registry of the International Society for Heart and Lung Transplantation: 31st official adult heart transplantation report\u20142014; focus theme: retransplantation","volume":"33","author":"Lund","year":"2014","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib22","unstructured":"U.S. Department of Health & Human Services. U.S Food and Drug Administration. Basiliximab product approval information\u2014licensing action. Available at: http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/approvalapplications\/therapeuticbiologicapplications\/ucm093365.htm or http:\/\/www.fda.gov. Accessed June 2, 2015."},{"key":"10.1016\/j.healun.2015.04.001_bib23","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/j.healun.2013.08.006","article-title":"The Registry of the International Society for Heart and Lung Transplantation: thirtieth official adult heart transplant report\u20142013; focus theme: age","volume":"32","author":"Lund","year":"2013","journal-title":"J Heart Lung Transplant"},{"key":"10.1016\/j.healun.2015.04.001_bib24","unstructured":"European Medicines Agency. Science Medicines Health. Pharmacovigilance Risk Assessment Committee recommendations on signals. Available at: http:\/\/www.ema.europa.eu."},{"key":"10.1016\/j.healun.2015.04.001_bib25","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1159\/000351643","article-title":"Thymoglobulin and its use in renal transplantation: a review","volume":"37","author":"Thiyagarajan","year":"2013","journal-title":"Am J Nephrol"},{"key":"10.1016\/j.healun.2015.04.001_bib26","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1056\/NEJM200003023420902","article-title":"Prevention of rejection in cardiac transplantation by blockade of the interleukin-2 receptor with a monoclonal antibody","volume":"342","author":"Beniaminovitz","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.healun.2015.04.001_bib27","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1056\/NEJMoa032953","article-title":"Daclizumab to prevent rejection after cardiac transplantation","volume":"352","author":"Hershberger","year":"2005","journal-title":"N Engl J Med"}],"container-title":["The Journal of Heart and Lung Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249815012048?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1053249815012048?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T08:29:53Z","timestamp":1760948993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1053249815012048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S1053249815012048"],"URL":"https:\/\/doi.org\/10.1016\/j.healun.2015.04.001","relation":{},"ISSN":["1053-2498"],"issn-type":[{"value":"1053-2498","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Induction with anti-thymocyte globulin in heart transplantation is associated with better long-term survival compared with basiliximab","name":"articletitle","label":"Article Title"},{"value":"The Journal of Heart and Lung Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.healun.2015.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}